SOPHiA GENETICS Reports Q1 Revenue Growth, Reaffirms FY26 Guidance, and Secures $14.5M via ATM Offering
SOPH sits 97% above its 52-week low of $2.59 on light trading volume (0.4× avg).
Summary
SOPHiA GENETICS reported 22% Q1 revenue growth and strong operational metrics, while securing $14.5 million through an ATM offering to bolster liquidity amidst ongoing losses and cash burn. The company reaffirmed its full-year guidance, targeting adjusted EBITDA breakeven by year-end 2026.
Key Events · Earnings and Guidance · SOPH
-
Strong Q1 Revenue Growth
Revenue increased 22% year-over-year to $21.7 million, driven by a record 108,000 genomic analyses and a Net Dollar Retention of 117%.
-
Significant Capital Raise via ATM Offering
The company secured $14.5 million in net proceeds from an at-the-market (ATM) offering, selling 2,864,872 ordinary shares to bolster liquidity.
-
Reaffirmed Full-Year Guidance
SOPHiA GENETICS reaffirmed its 2026 revenue guidance of $92M-$94M and adjusted EBITDA loss guidance of $29M-$32M, targeting breakeven by year-end 2026.
-
Ongoing Losses and Cash Burn
The company reported an IFRS net loss of $19.3 million and used $15.1 million in cash from operating activities during Q1 2026.
Analysis · SOPH · Technology
SOPHiA GENETICS SA reported strong Q1 2026 revenue growth of 22% year-over-year, driven by a record 108,000 genomic analyses and increased Net Dollar Retention. Despite this operational momentum, the company continues to incur significant IFRS net losses and cash burn from operations. The successful at-the-market (ATM) offering, which raised $14.5 million by selling 2,864,872 ordinary shares, is a critical financing event that provides necessary liquidity, offsetting the Q1 operating cash outflow. However, this capital raise also introduces dilution. The company also issued additional warrants in connection with a debt amendment, representing further potential dilution. SOPHiA GENETICS reaffirmed its full-year 2026 revenue and adjusted EBITDA loss guidance, maintaining a commitment to approaching adjusted EBITDA breakeven by the end of 2026 and achieving positive adjusted EBITDA in the second half of 2027. Investors should monitor the company's ability to sustain revenue growth, manage operating expenses, and reduce cash burn to achieve its profitability targets, especially given the ongoing need for capital.
At the time of this filing, SOPH was trading at $5.10 on NASDAQ in the Technology sector, with a market capitalization of approximately $379.1M. The 52-week trading range was $2.59 to $5.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.